CD274 and neoplasm: Tremelimumab was also included in a multicenter Phase I–II study combined with the PD-L1 antibody, durvalumab (MEDI4736), and the tumor microenvironment modulator polyICLC, a Toll like receptor-3 (TLR-3) agonist, in patients with several advanced, measurable, biopsy-accessible of cancers, including PCa (NCT02643303).